Physician profile
James Herndon
NPI 1831285915
$698.05
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $136.19 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $93.56 | 2019 | |
| Galderma Laboratories, L.P. | $64.54 | 2019 | |
| Pfizer INC. | $63.75 | 2019 | |
| Lilly USA, LLC | $61.01 | 2019 | |
| Janssen Biotech, INC. | $55.71 | 2019 | |
| Sun Pharmaceutical Industries INC. | $39.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.88 | 2019 | |
| Celgene Corporation | $34.49 | 2019 | |
| Almirall LLC | $33.66 | 2019 | |
| Sandoz INC. | $23.71 | 2019 | |
| Aclaris Therapeutics, INC. | $23.49 | 2019 | |
| Amgen INC. | $20.36 | 2019 | |
| Dusa Pharmaceuticals, INC. | $11.74 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Herndon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.